Fulton, B. et al. (2018) PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 8, pp. 12-16. (doi: 10.1016/j.ctro.2017.11.003)
|
Text
153362.pdf - Published Version Available under License Creative Commons Attribution. 691kB |
Abstract
Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Kelly, Mrs Caroline and Fulton, Ben and Nowicki, Dr Stefan and Morris, Miss Anna and James, Dr Allan and Stobo, Mr Jon and Chalmers, Professor Anthony |
| Authors: | Fulton, B., Short, S. C., James, A., Nowicki, S., McBain, C., Jefferies, S., Kelly, C., Stobo, J., Morris, A., Williamson, A., and Chalmers, A. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences College of Medical Veterinary and Life Sciences > School of Biodiversity, One Health & Veterinary Medicine |
| Journal Name: | Clinical and Translational Radiation Oncology |
| Publisher: | Elsevier |
| ISSN: | 2405-6308 |
| ISSN (Online): | 2405-6308 |
| Published Online: | 21 November 2017 |
| Copyright Holders: | Copyright © 2017 Elsevier Ireland Ltd. |
| First Published: | First published in Clinical and Translational Radiation Oncology 8:12-16 |
| Publisher Policy: | Reproduced under a Creative Commons License |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information